Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$157.12
-0.2%
$140.70
$91.86
$254.15
$7.72B1.491.03 million shs247,085 shs
Icon Plc stock logo
ICLR
Icon
$150.06
-0.5%
$139.88
$125.10
$347.72
$12.12B1.171.10 million shs486,301 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$164.24
-0.2%
$150.59
$134.65
$252.88
$28.41B1.31.65 million shs674,106 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$53.14
-0.1%
$49.94
$46.01
$83.62
$8.33B1.391.45 million shs843,085 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-0.24%+3.54%+13.27%+14.73%-21.99%
Icon Plc stock logo
ICLR
Icon
-0.51%+2.25%+12.18%-2.38%-52.81%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
-0.31%+3.95%+15.06%+6.22%-20.52%
Bio-Techne Corp stock logo
TECH
Bio-Techne
-0.08%+0.63%+8.93%+2.74%-25.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
4.0563 of 5 stars
2.12.00.04.72.22.51.9
Icon Plc stock logo
ICLR
Icon
4.3829 of 5 stars
4.33.00.00.01.83.32.5
IQVIA Holdings Inc. stock logo
IQV
IQVIA
4.9158 of 5 stars
4.42.00.04.63.21.72.5
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.9729 of 5 stars
4.25.01.74.22.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.19
Hold$171.859.37% Upside
Icon Plc stock logo
ICLR
Icon
2.60
Moderate Buy$213.0842.00% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.75
Moderate Buy$226.3237.80% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0035.50% Upside

Current Analyst Ratings Breakdown

Latest CRL, ICLR, TECH, and IQV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/23/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$188.00
5/23/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$188.00 ➝ $182.00
5/22/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/19/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$232.00 ➝ $177.00
5/15/2025
Icon Plc stock logo
ICLR
Icon
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$200.00 ➝ $173.00
5/15/2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$210.00 ➝ $190.00
5/14/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
5/14/2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$179.00
5/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.05B1.91$21.64 per share7.26$67.80 per share2.32
Icon Plc stock logo
ICLR
Icon
$8.28B1.46$19.95 per share7.52$117.92 per share1.27
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$15.41B1.84$16.57 per share9.91$33.43 per share4.91
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B7.19$2.31 per share22.98$13.13 per share4.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$22.20M-$0.65N/A14.285.33-0.66%15.19%6.93%8/6/2025 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$9.1816.359.811.849.25%11.46%6.49%7/23/2025 (Estimated)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$1.37B$7.3422.3813.461.838.61%29.16%6.96%7/28/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8264.8026.972.5310.89%13.17%10.17%8/6/2025 (Estimated)

Latest CRL, ICLR, TECH, and IQV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/28/2025Q2 2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.76N/AN/AN/A$3.96 billionN/A
7/23/2025Q2 2025
Icon Plc stock logo
ICLR
Icon
$3.18N/AN/AN/A$1.98 billionN/A
5/7/2025Q1 2025
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.06$2.34+$0.28$0.50$942.34 million$984.17 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
5/6/2025Q1 2025
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.63$2.70+$0.07$1.40$3.77 billion$3.83 billion
4/30/2025Q1 2025
Icon Plc stock logo
ICLR
Icon
$3.17$3.19+$0.02$1.90$2.03 billion$2.00 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.60%N/A39.02%N/A

Latest CRL, ICLR, TECH, and IQV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.78
1.43
1.16
Icon Plc stock logo
ICLR
Icon
0.36
1.27
1.27
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.19
0.82
0.82
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Icon Plc stock logo
ICLR
Icon
95.61%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
89.62%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Icon Plc stock logo
ICLR
Icon
44.00%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
1.60%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
20,10049.12 million48.48 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
88,000173.00 million170.23 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

Is Bio-Techne Stock Underperforming the Nasdaq?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$157.12 -0.37 (-0.23%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$157.12 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$150.06 -0.77 (-0.51%)
Closing price 07/3/2025 01:48 PM Eastern
Extended Trading
$150.06 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

IQVIA stock logo

IQVIA NYSE:IQV

$164.24 -0.41 (-0.25%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$163.14 -1.11 (-0.67%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$53.14 -0.05 (-0.08%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$53.14 0.00 (0.00%)
As of 07/3/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.